October 31, 2021
Video
Patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.
October 30, 2021
ACG represents the first major in-person conference since the COVID-19 pandemic.
October 29, 2021
Article
Even though COVID-19 infection disproportionately impacts minority patients, there’s no indication that vaccine intention differs depending on race in IBD patients.
October 28, 2021
This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.
Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.
October 27, 2021
In his lecture, The End of the Beginning: Megatrends in Gastroenterology, William Chey, MD, emphasizes the importance of a multidisciplinary integrated care approach to treating IBS.
An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.
October 26, 2021
Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.
A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.
Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.
Study Suggests Sickle Cell Trait as an Adverse Prognostic Factor for COVID-19
Atherosclerotic Plaque Found Highly Prevalent in Older Population in China
Vurolenatide Showing Promise Treating Short Bowel Syndrome
